Toronto Thromboprophylaxis Patient Safety Initiative
TOPPS
1 other identifier
interventional
1,895
1 country
1
Brief Summary
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE, is one of the common and preventable complications of hospital stay. VTE prophylaxis through the use of evidence-based anticoagulant medication options or mechanical prophylaxis have been shown to reduce this risk and improve patient safety. Despite an abundance of evidence, use of VTE prophylaxis remains low. This study assesses the effectiveness of quality improvement strategies (use of pre-printed orders, audit and feedback, involvement of the pharmacist as project need and as a reminder to the physician, and education of staff) on use of appropriate VTE prophylaxis. The study aims to measure if the use of these strategies improves the use of VTE prophylaxis and therefore, improves patient safety and patient care by reducing the risk of developing DVT or PE.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2006
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2009
CompletedFirst Submitted
Initial submission to the registry
April 3, 2013
CompletedFirst Posted
Study publicly available on registry
June 5, 2013
CompletedResults Posted
Study results publicly available
September 23, 2014
CompletedSeptember 23, 2014
September 1, 2014
2.7 years
April 3, 2013
August 11, 2014
September 16, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Patients Prescribed Appropriate VTE Prophylaxis
Rates of appropriate VTE prophylaxis were determined as the number of patients who received VTE prophylaxis as a proportion of the number of patient at risk. Rates reported are for the active phases (phase 1 and phase 2) and compare intervention to control. Appropriate VTE prophylaxis was defined as: in "Hip Fracture Surgery" - evidence-based VTE prophylaxis ordered within 24 of admission, restarted within 24 hours after surgery and continued for at least 10 days post-discharge in "Major General Surgery" - evidence-based VTE prophylaxis ordered within 24 hours post-surgery and continued for the duration of hospital stay in "Acute Medical Illness" - evidence-based VTE prophylaxis ordered within 24 hours of admission and continued for the duration of hospital stay. Evidence-based VTE prophylaxis was determined to be according to the American College of Chest Physicians (ACCP) guidelines. The 9th version was the most current version at the time of the study.
End of study (end of phase 2) - measured over duration of hospital stay.
Study Arms (6)
AMI - Knowledge Translation toolkit
EXPERIMENTALAMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
AMI - Usual Care
NO INTERVENTIONUsual care
MGS - Knowledge Translation Toolkit
EXPERIMENTALKnowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
MGS - Usual Care
NO INTERVENTIONUsual Care
HFS - Knowledge Translation Toolkit
EXPERIMENTALKnowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
HFS - Usual Care
NO INTERVENTIONUsual Care
Interventions
KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
Eligibility Criteria
You may qualify if:
- age at least 18 years
- at risk for VTE
You may not qualify if:
- on therapeutic anticoagulation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sunnybrook Health Sciences Centrelead
- North York General Hospitalcollaborator
- Michael Garron Hospitalcollaborator
- Trillium Health Centrecollaborator
- Lakeridge Health Corporationcollaborator
- York Central Hospital, Ontariocollaborator
- Scarborough General Hospitalcollaborator
- Markham Stouffville Hospitalcollaborator
Study Sites (1)
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Related Publications (1)
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
PMID: 15383478BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Artemis Diamantouros
- Organization
- Sunnybrook HSC
Study Officials
- PRINCIPAL INVESTIGATOR
William H Geerts, MD
Sunnybrook Health Sciences Centre
Publication Agreements
- PI is Sponsor Employee
- Yes
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- KT Pharmacist
Study Record Dates
First Submitted
April 3, 2013
First Posted
June 5, 2013
Study Start
July 1, 2006
Primary Completion
March 1, 2009
Study Completion
March 1, 2009
Last Updated
September 23, 2014
Results First Posted
September 23, 2014
Record last verified: 2014-09